Detalles de la búsqueda
1.
Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.
Pharm Res;
36(3): 49, 2019 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30746556
2.
Probing the mechanism of reduced in vivo potency of insulin detemir.
Expert Opin Drug Metab Toxicol;
19(4): 225-228, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272319
3.
Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review.
J Diabetes Sci Technol;
17(2): 290-301, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36540004
4.
Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5.
Diabetes Technol Ther;
24(1): 10-17, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34524005
5.
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology.
Trends Pharmacol Sci;
42(8): 620-639, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34148677
6.
Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to NovoLog®.
Comput Methods Programs Biomed;
205: 106087, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33873075
7.
A novel high-affinity peptide antagonist to the insulin receptor.
Biochem Biophys Res Commun;
376(2): 380-3, 2008 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-18782558
8.
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Diabetes;
51(2): 424-9, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11812750
9.
Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener.
Diabetes;
53(4): 1089-95, 2004 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15047626
10.
NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat.
Diabetes;
52(10): 2513-8, 2003 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-14514634
11.
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
Diabetes;
52(7): 1786-91, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12829647
12.
Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets.
Diabetes;
53(7): 1706-13, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15220194
13.
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Diabetes;
53(5): 1187-94, 2004 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15111485
14.
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.
Diabetes Care;
25(8): 1398-404, 2002 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12145241
15.
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
J Med Chem;
45(4): 789-804, 2002 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-11831892
16.
GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.
Br J Pharmacol;
140(1): 123-32, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12967942
17.
Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.
Metabolism;
53(4): 441-7, 2004 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15045689
18.
NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.
Eur J Pharmacol;
451(2): 217-25, 2002 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-12231394
19.
Phase-locking regions in a forced model of slow insulin and glucose oscillations.
Chaos;
5(1): 193-199, 1995 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12780173
20.
Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model.
J Pharm Pharmacol;
65(2): 230-5, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23278690